The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

Disclosed are a novel hypoxia-inducible factor 1? (HIF-1?) inhibitor, a method of preparing the same, and a pharmaceutical composition for preventing or treating an angiogenesis-related eye disease containing the same as an active ingredient. The compound of Example provided according to an embodiment of the present invention is capable of effectively inhibiting HIF-1? and is thus useful as a pharmaceutical composition for preventing or treating an angiogenesis-related eye disease.

The present invention refers to aryl beta diketones of the formula (I)

##STR00001## wherein Y, R.sup.1, R.sup.2 and R.sup.3 have the meaning R.sup.1 is selected from the group consisting of hydrogen, C.sub.1-C.sub.4 alkyl, hydroxyl, methoxy, CF.sub.3 and F; R.sup.2 is selected from the group consisting of methyl and ethyl; R.sup.3 is selected from the group consisting of methyl and ethyl; and Y is a bivalent residue selected from the group consisting of C(O); CH.sub.2CH.sub.2C(O); CR.sup.IR.sup.IIC(O), wherein R.sup.I and R.sup.II are independently selected from hydrogen and methyl; and CHR.sup.IIICHR.sup.IVC(O), wherein R.sup.III and R.sup.IV are independently selected from hydrogen and methyl with the proviso, that R.sup.IIIR.sup.IV are hydrogen or either R.sup.III or R.sup.IV is methyl. The invention further refers to fragrance compositions and fragranced articles comprising them.

The present invention refers to aryl beta diketones of the formula (I)

##STR00001## wherein Y, R.sup.1, R.sup.2 and R.sup.3 have the meaning R.sup.1 is selected from the group consisting of hydrogen, C.sub.1-C.sub.4 alkyl, hydroxyl, methoxy, CF.sub.3 and F; R.sup.2 is selected from the group consisting of methyl and ethyl; R.sup.3 is selected from the group consisting of methyl and ethyl; and Y is a bivalent residue selected from the group consisting of C(O); CH.sub.2CH.sub.2C(O); CR.sup.IR.sup.IIC(O), wherein R.sup.I and R.sup.II are independently selected from hydrogen and methyl; and CHR.sup.IIICHR.sup.IVC(O), wherein R.sup.III and R.sup.IV are independently selected from hydrogen and methyl with the proviso, that R.sup.IIIR.sup.IV are hydrogen or either R.sup.III or R.sup.IV is methyl. The invention further refers to fragrance compositions and fragranced articles comprising them.

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.